… of patients attending a specialty Autoimmune Blistering Disease Clinic at a single academic
… Systemic steroid included prednisone and intramuscular kenalog. Conventional steroid-…

… In our study, we did not account for the usage of glucocorticoids (systemic and topical) or
rituximab after baseline, as we did not aim to study potential effect modification by ABD …

… Thereafter, members of the EADV Task force Autoimmune blistering diseases (notation … a
0.5 mg/kg/day starting dose of prednisone allows disease control to be achieved at day 21 in 75…

… Treatment options for autoimmune bullous diseases (AIBD) are currently limited to
corticosteroids and traditional immunomodulants and immunosuppressants that are associated with …

… Glucocorticoid use in patients with autoimmune bullous disease is associated with … The
hyperglycaemic complications arising from glucocorticoid use have been well-documented and …

… and pemphigoid diseases. … prednisone dose and the number of severe adverse events
were lower with rituximab combined with short-term corticosteroid therapy than with corticosteroid …

… disease activity in all autoimmune blistering diseases. This score assesses the degree of …
membrane pemphigoid; ie, with agents such as rituximab, prednisone, dapsone, or IVIG. …

… and are often on immunosuppressive medications, including systemic steroids, rituximab,
and other biologic agents. These medications, most notably rituximab, are responsible for …

… BP is an autoimmune blistering disease, characterized by an immune response against
BP180 and BP230. It mainly affects elderly patients and its incidence is growing in parallel with …

… human papillomavirus (Gardasil) Pemphigoid (n = 2), PV (n = 1) … and autoimmune diseases
including PV, PF, and pemphigoid. … after topical/oral corticosteroids Exacerbation after the …